BVF Inc’s TScan Therapeutics TCRX Stock Holding History

BVF Inc’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.45M	Hold	5,564,290	–	–	0.14%	38
2026 Q1	$5.62M	Buy	5,564,290 +338,216	+6%	+$361K	0.18%	36
2025 Q4	$5.23M	Hold	5,226,074	–	–	0.18%	37
2025 Q3	$9.51M	Hold	5,226,074	–	–	0.39%	34
2025 Q2	$7.58M	Buy	5,226,074 +336,600	+7%	+$486K	0.27%	34
2025 Q1	$6.75M	Buy	4,889,474 +1,900,000	+64%	+$4.11M	0.28%	38
2024 Q4	$9.09M	Hold	2,989,474	–	–	0.31%	38
2024 Q3	$14.9M	Hold	2,989,474	–	–	0.44%	32
2024 Q2	$17.5M	Hold	2,989,474	–	–	0.49%	35
2024 Q1	$23.7M	Hold	2,989,474	–	–	0.65%	32
2023 Q4	$17.4M	Hold	2,989,474	–	–	0.44%	40
2023 Q3	$7.65M	Hold	2,989,474	–	–	0.21%	49
2023 Q2	$7.47M	Buy	+2,989,474	New	+$8.02M	0.21%	48

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BVF Inc's TCRX Position: Q2 2026 in Review

BVF Inc held its TScan Therapeutics (TCRX) position steady in Q2 2026 at 5,564,290 shares worth $5.45M. The position accounts for 0.14% of the portfolio, ranked #38.

BVF Inc first reported a position in TCRX in Q2 2023 and has held it in 13 quarters since. The position peaked at $23.7M in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

BVF Inc held 5,564,290 shares of TScan Therapeutics worth $5.45M as of Q2 2026.
BVF Inc left its TScan Therapeutics share count unchanged in Q2 2026.
TScan Therapeutics made up 0.14% of BVF Inc's portfolio in Q2 2026, its #38 holding.
BVF Inc first reported a position in TScan Therapeutics in Q2 2023 and has held it in 13 quarters since.
BVF Inc's TScan Therapeutics position peaked at $23.7M in Q1 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on BVF Inc's 13F filing for Q2 2026, filed 14 Aug 2026.